newsfilter
← Latest News
Business Wire·

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 Jakafi®/Jakafi XR™ (ruxolitinib) net sales of $827